Status:
COMPLETED
Nesiritide - Dilated Cardiomyopathy
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
Scios, Inc.
Conditions:
Dilated Cardiomyopathy
Eligibility:
All Genders
Up to 21 years
Phase:
NA
Brief Summary
Nesiritide is a rapid vasodilator that mimics the action of an endogenous hormone - human B-type natriuretic peptide (BNP). BNP is produced naturally in the ventricles of the heart in response to stre...
Eligibility Criteria
Inclusion
- Diagnosis of dilated cardiomyopathy
- Less than 21 years of age
- Patient admitted to the intensive care unit
- Patient requiring placement of a Swan-Ganz catheter
- Patient's hemodynamics or clinical condition requires the use of a Swan-Ganz catheter for 26 hours following the cardiac catheterization.
- Patient has signed an IRB approved consent form.
Exclusion
- Severe hemodynamic instability including patients requiring ECMO
- Cardiac catheterization not indicated
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2005
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00709163
Start Date
December 1 2003
End Date
November 1 2005
Last Update
July 3 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mattel Children's Hospital at UCLA
Los Angeles, California, United States, 90095